Company Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 15/05/2026			5-day change	1st Jan Change
188,800.00 ^KRW	-3.23%		-6.77%	+4.31%

05-13	Celltrion USA, Inc. announced that it has received $516.1 million in funding from Celltrion, Inc.	CI
05-08	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 22, 2026.	CI

Business description: Celltrion, Inc.

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Number of employees: 2,680

Sales by Activity: Celltrion, Inc.

Fiscal Period: December	2021 (KRW)	2022 (KRW)	2023 (KRW)	2024 (KRW)	2025 (KRW)
Biopharmaceutical	1,616B	1,937B	1,873B	6,070B	6,033B
Chemical Drugs	557B	654B	501B	531B	557B
Other	3.05B	3.88B	5.14B	5.82B	6.74B
Intersectoral Insider Transaction Reconciliation	-264B	-311B	-203B	-3,050B	-2,434B

See all business segments

Geographical breakdown of sales: Celltrion, Inc.

Fiscal Period: December	2021 (KRW)	2022 (KRW)	2023 (KRW)	2024 (KRW)	2025 (KRW)
South Korea	2,015B	2,324B	2,262B	4,184B	3,526B
Europe	-	-	-	1,862B	2,145B
North America	-	-	-	168B	420B
Asia	76.42B	140B	117B	252B	344B
Latin America	-	-	-	-	162B
Central and South America	-	-	-	141B	-
Americas	84.61B	131B	-	-	-
Consolidation Adjustment	-264B	-311B	-203B	-3,050B	-2,434B

See all geographic segments

Executive Committee: Celltrion, Inc.

Manager	Title	Age	Since
Wu-Sung Ki CEO	Chief Executive Officer	65	19/03/2015
Jin-Seok Seo CEO	Chief Executive Officer	42	25/03/2021
Hyeok-Jae Lee PSD	President	50	12/02/2026
Ho-Seop Lee DFI	Director of Finance/CFO	51	-
Gi-Seong Kw CTO	Chief Tech/Sci/R&D Officer	57	-

See CELLTRION, INC. governance

Composition of the Board of Directors: Celltrion, Inc.

Director	Title	Age	Since
Jung-Jin Seo CHM	Chairman	68	-
Hyung-Ki Kim BRD	Director/Board Member	61	31/03/2005
Geun-Young Kim BRD	Director/Board Member	66	-
Dae-Hyeon Yoo BRD	Director/Board Member	67	-
Soon-Woo Lee BRD	Director/Board Member	75	-
Jae-Sik Lee BRD	Director/Board Member	68	-
Young-Hye Ko BRD	Director/Board Member	71	24/03/2022
Wu-Sung Ki BRD	Director/Board Member	65	23/04/2007
Jin-Seok Seo BRD	Director/Board Member	42	25/03/2021
Joong-Jae Lee BRD	Director/Board Member	63	27/12/2023

Composition of the Board of Directors

Shareholders: Celltrion, Inc.

Name	Equities	%	Valuation
Jung-Jin Seo 32.08 %	71,195,305	32.08 %	9 624 M ₩
CELLTRION, INC. 0.2203 %	488,977	0.2203 %	66 M ₩
Sjunde AP-fonden 0.1607 %	356,717	0.1607 %	48 M ₩
State Street Global Advisors Ltd. 0.1503 %	333,580	0.1503 %	45 M ₩
Heon-Young Yoo 0.1232 %	273,419	0.1232 %	37 M ₩

List of CELLTRION, INC. shareholders

Holdings: Celltrion, Inc.

Name	Equities	%	Valuation
CELLTRION PHARM, INC. 54.8%	24,416,241	54.8%	924 M $
CELLTRION, INC. 0.22%	488,977	0.22%	66 M $
BIOTOXTECH CO., LTD. 10.22%	1,631,134	10.22%	4 M $

Company details: Celltrion, Inc.

Celltrion, Inc.

23 Academy-ro

22014, Inchon

+82 3 2850 5000

http://www.celltrion.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CELLTRION, INC.	-3.23%	-6.77%	+27.25%	+23.75%	27.41B
LONZA GROUP AG	-1.01%	-3.46%	-17.74%	-18.31%	42.28B
BEONE MEDICINES AG	-3.73%	-6.04%	+29.90%	+22.07%	33.87B
REVOLUTION MEDICINES, INC.	-2.55%	+2.71%	+269.32%	+448.83%	31.78B
IQVIA HOLDINGS INC.	-0.91%	-5.37%	+20.43%	-11.67%	28.49B
ASCENDIS PHARMA A/S	-2.03%	+0.77%	-	-	15.25B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+6.21%	-2.39%	+170.16%	+4,385.95%	13.31B
IONIS PHARMACEUTICALS, INC.	-1.92%	-1.95%	+125.01%	+104.83%	12.51B
EUROFINS SCIENTIFIC SE	-0.20%	-0.74%	+8.45%	-1.20%	12.2B
MEDPACE HOLDINGS, INC.	-0.93%	-2.06%	+40.10%	+96.92%	11.97B
Average	-1.06%	-2.67%	+74.77%	+561.24%	22.91B
Weighted average by Cap.	-1.58%	-2.37%	+68.10%	+352.53%